Every 8-K that Vera Therapeutics, Inc. (VERA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERA filings page.
Vera Therapeutics, Inc. reported second quarter 2026 results and highlighted a major regulatory milestone. The company received FDA accelerated approval for TRUTAKNA in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression and has begun a U.S. commercial launch. TRUTAKNA is the first approved therapy that inhibits both BAFF and APRIL, with Phase 3 ORIGIN data showing a 46% proteinuria reduction from baseline at 36 weeks and a 42% reduction versus placebo, plus a 68% reduction in galactose-deficient IgA1 and hematuria resolution in 81% of affected patients.
For the quarter ended June 30, 2026, Vera reported a net loss of $109.5 million, or $1.52 per share, compared with a $76.5 million loss, or $1.20 per share, a year earlier. Operating expenses rose to $112.5 million from $80.1 million, reflecting higher research and development and general and administrative spending. As of June 30, 2026, the company held $499.2 million in cash, cash equivalents and marketable securities and has access to up to $425 million under a debt facility, subject to conditions, to support its TRUTAKNA launch and ongoing clinical programs. Management expects the ORIGIN 3 final efficacy analysis in Q3 2026, an sBLA filing in Q4 2026, and is targeting potential full approval in 2027.
Vera Therapeutics, Inc. is changing its regulatory leadership. Effective August 3, 2026, Nancy Bowman, M.D., Ph.D. will become the company’s Chief Regulatory Officer. On the same date, current Chief Regulatory Officer William Turner will step down from that role and move into a new position as Special Advisor for Regulatory Affairs.
The company disclosed this leadership transition under the category covering departures and appointments of certain officers.
Vera Therapeutics reported that the U.S. Food and Drug Administration has granted accelerated approval for its drug TRUTAKNA™ (atacicept-vymj) as of July 7, 2026. The therapy is approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
This represents Vera’s transition into a commercial-stage company for IgA nephropathy, with an FDA-cleared product aimed at a serious kidney disease where reducing protein in the urine can help slow long-term damage.
Vera Therapeutics reported a key regulatory update for its drug candidate atacicept in adults with IgA nephropathy. The company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan intended to support potential full approval.
The eGFR results from ORIGIN 3 are now expected in the third quarter of 2026. If those results are supportive, Vera plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026. The company cautions that these are forward-looking statements subject to clinical, regulatory, and broader business risks.
Vera Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders. As of the March 24, 2026 record date, 71,713,905 shares of Class A common stock were outstanding and entitled to vote.
Stockholders elected three Class II directors to terms ending at the 2029 annual meeting: Michael M. Morrisey, Ph.D. (45,288,710 votes for, 13,814,671 withheld, 2,863,469 broker non-votes), Patrick G. Enright (54,697,296 for, 4,406,085 withheld, 2,863,469 broker non-votes), and James R. Meyers (58,946,269 for, 157,112 withheld, 2,863,469 broker non-votes).
Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 61,834,842 votes for, 44,710 against, and 87,298 abstentions. In an advisory vote, stockholders approved executive compensation, with 56,585,568 votes for, 2,433,537 against, 84,276 abstentions, and 2,863,469 broker non-votes.
Vera Therapeutics reported first-quarter 2026 results and highlighted progress toward potential FDA accelerated approval of atacicept for IgA nephropathy, which is under Priority Review with a PDUFA date of July 7, 2026. The company posted a net loss of $121.0 million, or $1.69 per share, compared with a net loss of $51.7 million, or $0.81 per share, a year earlier as research and development and general and administrative spending rose sharply. Vera ended March 31, 2026 with $596.8 million in cash, cash equivalents and marketable securities and believes this, together with its debt facility, will fund operations through potential atacicept approval and U.S. commercial launch and beyond.
Vera Therapeutics reported that its board appointed Christopher Hite as a Class III director effective March 5, 2026, with his initial term running until the 2027 annual stockholders’ meeting. His compensation follows the company’s non-employee director policy.
On joining the board, Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share. The option vests monthly over three years, subject to his continued service. He will also receive an annual cash retainer of $45,000, pro-rated for 2026.
Beginning with the 2027 annual meeting, Hite will be eligible each year for an option to buy up to the lesser of 18,000 shares or the number of shares with a grant date fair value not above $400,000, vesting by the next annual meeting or one year from grant. He will sign the company’s standard indemnification agreement, and the company notes there were no special arrangements or related-person transactions tied to his selection.
Vera Therapeutics reported a larger full-year 2025 net loss of $299.6 million, or $4.66 per share, compared with a $152.1 million loss a year earlier, as research and development and general and administrative expenses rose to a combined $315.5 million. Net cash used in operating activities was $241.1 million.
The company ended 2025 with $714.6 million in cash, cash equivalents, and marketable securities and completed equity and debt financings with combined potential gross proceeds of $800 million, which it believes can fund operations beyond potential approval and U.S. commercial launch of atacicept. Vera highlighted positive Phase 3 ORIGIN data for atacicept in IgA nephropathy and noted the FDA has granted priority review to its Biologics License Application, with a PDUFA action date of July 7, 2026 and a planned U.S. launch in mid-2026, if approved.
Vera Therapeutics, Inc. reported a leadership change, stating that Jason Carter will no longer serve as the company’s Chief Legal Officer, effective December 24, 2025. The change was disclosed as an officer departure under a current report, with no additional details provided about his future role or any replacement.
Vera Therapeutics, Inc. announced that its board of directors has appointed James R. Meyers as a Class II director, effective immediately. His initial term will run until the company’s 2026 annual meeting of stockholders, and he has also been appointed to the board’s Audit Committee.
Upon joining the board, Mr. Meyers received a nonstatutory stock option to purchase 25,000 shares of Class A common stock, vesting monthly over three years under the company’s non-employee director compensation policy. He will receive an annual cash retainer of $40,000 for board service and $10,000 for Audit Committee service, pro-rated for 2025. Beginning with the 2026 annual meeting, he will be eligible for an annual option grant for up to the lesser of 14,000 shares or options with a grant date fair value of not more than $400,000, subject to standard vesting tied to continued service.
Vera Therapeutics (VERA) reported positive Phase 3 ORIGIN data for atacicept in IgA nephropathy, presented as a late-breaking oral at ASN Kidney Week 2025 and published in The New England Journal of Medicine. Participants on atacicept achieved a 46% reduction from baseline in proteinuria (24-hour UPCR) and a statistically significant, clinically meaningful 42% reduction versus placebo (p<0.0001) at week 36.
Efficacy was consistent across prespecified subgroups, including age, sex, race, region, baseline proteinuria, baseline eGFR, and baseline SGLT2i use. Secondary endpoints improved: Gd-IgA1 decreased by 68% and hematuria resolved in 81% of those with baseline hematuria. Safety across the ORIGIN program appears favorable and comparable to placebo, with fewer serious adverse events on atacicept (1 [0.5%]) than placebo (11 [5%]) and no deaths reported.
Vera Therapeutics (VERA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and includes recent corporate updates.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. Item 9.01 lists the exhibits. The report was signed by Sean Grant, Chief Financial Officer, on November 5, 2025.
Vera Therapeutics (Nasdaq: VERA) filed an 8-K announcing a new Sales Agreement with TD Securities (USA) LLC (TD Cowen) dated 5 Aug 2025. The arrangement establishes an at-the-market (ATM) equity program permitting the company to issue and sell up to $200 million of Class A common stock under its effective shelf registration statement (Form S-3, File No. 333-282861).
TD Cowen will act as sales agent and/or principal, executing ordinary-course, block or negotiated transactions on Nasdaq or other trading venues. The company will pay a commission of up to 3.0 % of gross proceeds. Vera is under no obligation to sell shares, and either party may terminate the agreement by written notice. The filing simultaneously terminates the prior Sales Agreement dated 3 Jun 2022.
The program enhances funding flexibility without adding debt but could create dilution and share-price overhang if the full $200 million capacity is utilized.